Methylation of Wnt antagonist genes: A useful prognostic marker for myelodysplastic syndrome

Annals of Hematology

Volumn 92, Issue 2, 2013, Pages 199-209

  Wang, Hong ^a,b   Fan, Rong ^c   Wang, Xiao Qin ^c   Wu, De Pei ^a,b   Lin, Guo Wei ^c   Xu, Yang ^a,b   Li, Wei Yang ^a,b  

^a SOOCHOW UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

MDS; Methylation; Prognosis; SFRP; Wnt pathway

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; CANCER RISK; CELL CYCLE REGULATION; CONTROLLED STUDY; DISEASE MARKER; DKK 1 GENE; DKK 3 GENE; DNA METHYLATION; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MYELODYSPLASTIC SYNDROME; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SEQUENCE ANALYSIS; SFRP1 GENE; SFRP2 GENE; SFRP4 GENE; SFRP5 GENE; SIGNAL TRANSDUCTION; SURVIVAL RATE; UPREGULATION; WNT ANTAGONIST GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AZACITIDINE; BETA CATENIN; BONE MARROW CELLS; CELL CYCLE; CELL LINE; CELL NUCLEUS; CYTOPLASM; DNA METHYLATION; EYE PROTEINS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; WNT PROTEINS; WNT SIGNALING PATHWAY; YOUNG ADULT;

EID: 84872290679     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1595-y     Document Type: Article

References (38)

1. Cadigan KM, Nusse R (1997) Wnt signaling: a common theme in animal development. Genes Dev 11:3286-305
2. Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434:843-50
3. Widelitz R (2005) Wnt signaling through canonical and non-canonical pathways: recent progress. Growth Factors 23:111-6
4. Staal FJ, Clevers HC (2005) WNT signalling and haematopoiesis: a WNT-WNT situation. Nat Rev Immunol 5:21-30
5. Gregorieff A, Clevers H (2005) Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev 19:877-90
6. Lee HC, Kim M, Wands JR (2006) Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci 11:1901-15
7. Kawano Y, Kypta R (2003) Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116:2627-34
8. Roman-Gomez J, Cordeu L, Agirre X, Jimenez-Velasco A, San Jose-Eneriz E, Garate L et al (2007) Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 109:3462-9
9. Valencia A, Roman-Gomez J, Cervera J, Such E, Barragan E, Bolufer P et al (2009) Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. Leukemia 23:1658-66
10. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K et al (2003) A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423:409-14
11. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T et al (2003) Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423:448-52
12. Van Den Berg DJ, Sharma AK, Bruno Eand Hoffman R (1998) Role of members of the Wnt gene family in human hematopoiesis. Blood 92:3189-202
13. Austin TW, Solar GP, Ziegler FC, Liem Land Matthews W (1997) A role for the Wnt gene family in hematopoiesis: expansion of multilineage progenitor cells. Blood 89:3624-35
14. Tickenbrock L, Schwable J, Wiedehage M, Steffen B, Sargin B, Choudhary C et al (2005) Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood 105:3699-706
15. Ysebaert L, Chicanne G, Demur C, De Toni F, Prade-Houdellier N, Ruidavets JB et al (2006) Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 20:1211-6
16. Xu J, Suzuki M, Niwa Y, Hiraga J, Nagasaka T, Ito M et al (2008) Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 140:394-401
17. Jaffe E S, Harris, N.L., Stein, H. & Vardiman, J.W. (Eds.)(2001). Tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours.
18. Mitelman FKS, Basal (1995). An International System for Human Cytogenetic Nomenclature.
19. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-88
20. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD et al (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62:65-74
21. Inman GJ, Nicolas FJ, Hill CS (2002) Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. Mol Cell 10:283-94
22. Mamidipudi V, Zhang J, Lee KC, Cartwright CA (2004) RACK1 regulates G1/S progression by suppressing Src kinase activity. Mol Cell Biol 24:6788-98
23. Heaney ML, Golde DW (1999) Myelodysplasia. N Engl J Med 340:1649-60
24. Smalley MJ, Dale TC (1999) Wnt signalling in mammalian development and cancer. Cancer Metastasis Rev 18:215-30
25. Weerkamp F, van Dongen JJ, Staal FJ (2006) Notch and Wnt signaling in T-lymphocyte development and acute lymphoblastic leukemia. Leukemia 20:1197-205
26. Simon M, Grandage VL, Linch D, Cand Khwaja A (2005) Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene 24:2410-20
27. Chim CS, Pang R, Fung TK, Choi C, Land Liang R (2007) Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 21:2527-36
28. Jost E, Schmid J, Wilop S, Schubert C, Suzuki H, Herman JG et al (2008) Epigenetic inactivation of secreted Frizzled-related proteins in acute myeloid leukaemia. Br J Haematol 142:745-53
29. Veeck J, Geisler C, Noetzel E, Alkaya S, Hartmann A, Knuchel R et al (2008) Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. Carcinogenesis 29:991-8
30. Melkonyan HS, Chang WC, Shapiro JP, Mahadevappa M, Fitzpatrick PA, Kiefer MC et al (1997) SARPs: a family of secreted apoptosis-related proteins. Proc Natl Acad Sci U S A 94:13636-41
31. Stambolic V, Ruel L, Woodgett JR (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6:1664-8
32. Lu Z, Ghosh S, Wang Zand Hunter T (2003) Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 4:499-515
33. Kobayashi K, Ouchida M, Tsuji T, Hanafusa H, Miyazaki M, Namba M et al (2002) Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells. Gene 282:151-8
34. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Barrios M et al (2004) Transcriptional silencing of the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia. Br J Cancer 91:707-13
35. Suzuki R, Onizuka M, Kojima M, Shimada M, Fukagawa S, Tsuboi K et al (2007) Preferential hypermethylation of the Dickkopf-1 promoter in core-binding factor leukaemia. Br J Haematol 138:624-31
36. Kornblith AB, Herndon JE 2nd, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF et al (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia Group B study. J Clin Oncol 20:2441-52
37. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL et al (2006) Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24:3895-903
38. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429-40